Hypothesis

IPA‑PXR signaling enhances sleep‑dependent glymphatic clearance by promoting astrocytic aquaporin‑4 (AQP4) polarization and reducing systemic inflammation that fragments sleep.

Mechanistic rationale

• IPA produced by gut Clostridium sporogenes activates intestinal PXR, tightening the barrier and lowering circulating LPS (see 1 and 2).
• Reduced endotoxemia diminishes TLR4/NF‑κB driven cytokine surges that otherwise fragment NREM sleep and impair astrocytic function (3).
• IPA crosses the BBB and binds neuronal and astrocytic PXR (4). In astrocytes, PXR acts as a transcription factor that upregulates Aqp4 and promotes its localization to perivascular endfeet, a prerequisite for efficient CSF‑ISF exchange.
• During sleep, norepinephrine troughs allow CSF influx; heightened AQP4 polarity accelerates clearance of soluble Aβ, tau, and metabolic waste, effectively performing the “nightly verdict” on synaptic substrates.

Testable predictions

1. Pharmacological: Oral IPA supplementation in aged mice will increase perivascular AQP4 signal (immunofluorescence) and boost CSF‑tracer influx during NREM sleep compared with vehicle.
2. Genetic: Astrocyte‑specific PXR knockout (Aldh1l1‑Cre; Nr1i2^fl/fl^) will abolish the IPA‑induced AQP4 upregulation and glymphatic enhancement, despite intact gut barrier.
3. Microbiota: Colonization of germ‑aged mice with IPA‑producing C. sporogenes will restore sleep‑linked glymphatic flux, whereas a non‑IPA producing strain will not.
4. Inflammatory: Measures of serum IL‑6 and TNF‑α will correlate inversely with glymphatic clearance rates; IPA treatment will lower cytokines and improve flux.

Experimental outline

• Animals: Young (3 mo) and aged (18‑20 mo) C57BL/6 mice; plus Nr1i2^−/−^ and astrocyte‑Pxr conditional KO lines.
• Interventions: IPA (10 mg/kg, oral gavage) or vehicle for 2 weeks; antibiotic cocktail to deplete endogenous IPA producers; fecal microbiota transplant (FMT) from IPA‑high donors.
• Readouts:
  • Sleep architecture via EEG/EMG (quantify NREM duration and delta power).
  • Glymphatic flux: intrathecal injection of fluorescently labeled CSF tracer (e.g., Alexa‑647‑albumin) and quantification of brain parenchymal clearance after 30 min of NREM using two‑photon microscopy.
  • AQP4 expression and polarization: confocal immunostaining of perivascular GFAP^−^ areas.
  • Barrier integrity: FITC‑dextran permeability assay; serum LPS ELISA.
  • Inflammatory cytokines: multiplex ELISA of serum and hippocampal homogenates.
• Controls: PXR antagonist (ketoconazole) co‑administration; inactive IPA analog.

Falsifiability

If IPA fails to increase AQP4 polarity or glymphatic clearance in wild‑type mice, or if astrocyte‑specific PXR loss does not block the effect, the hypothesis is refuted. Likewise, if barrier improvement occurs without corresponding glymphatic enhancement, the gut‑brain‑sleep link would be insufficient.

Implications

Demonstrating that a microbial metabolite can tune the brain’s nocturnal waste‑clearance machinery would reposition sleep hygiene as a modifiable lever of gut‑brain signaling, opening prebiotic or probiotic strategies to mitigate age‑related cognitive decline.